Elanco

ADM Board of Directors Enhances R&D, Innovation Expertise with Nomination of Elanco Executive Ellen de Brabander

Retrieved on: 
Tuesday, March 14, 2023
Agriculture, Natural Resources, Consumer, Pets, Other Natural Resources, Multimedia, Research, Retirement, Royal Netherlands Chemical Society, NYSE, Massachusetts Institute of Technology, Partnership, Boehringer Ingelheim, DSM, Yves De Brabander, Merck & Co., Schering-Plough, Investment, Leiden University, Animal, Food safety, ADM, Growth, Innovation, Publication, Molecular biology, Doctor of Philosophy, PepsiCo, Central European Institute of Technology, European Institute, Public policy, Management, Elanco

ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced that its Board of Directors has nominated Elanco executive vice president for Innovation and Regulatory Affairs, Dr. Ellen de Brabander, to stand for election to the Board at the company’s upcoming Annual Stockholders’ Meeting on May 4, 2023.

Key Points: 
  • ADM (NYSE: ADM), a global leader in human and animal nutrition, today announced that its Board of Directors has nominated Elanco executive vice president for Innovation and Regulatory Affairs, Dr. Ellen de Brabander, to stand for election to the Board at the company’s upcoming Annual Stockholders’ Meeting on May 4, 2023.
  • De Brabander has also held executive leadership positions in Boehringer Ingelheim (then known as Merial), Merck Animal Health (previously Intervet), and DSM.
  • ADM also announced that Lead Director Donald Felsinger will retire from the Board, having reached the retirement age of 75.
  • “When Don Felsinger joined our Board of Directors in 2009, ADM was a very different company,” Luciano said.

Elanco Animal Health Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Tuesday, February 21, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, EBITDA, JAK, Cattle, North American Pet Health Insurance Association, ERP, Dog, Diabetes, Methane, GAAP, Farm Animal, Pressure, Research, Travel, FDA, Dermatology, Growth, Advertising, Tax, CER, Tyrosine kinase inhibitor, U.S. FDA, Sale, Bayer, Selection, Cat, Pig, Vaccine, Poultry, EPA, Pharmaceutical industry, Video game, Elanco

Asset impairment, restructuring, and other special charges were $32 million in the fourth quarter of 2022, compared to $110 million in the fourth quarter of 2021.

Key Points: 
  • Asset impairment, restructuring, and other special charges were $32 million in the fourth quarter of 2022, compared to $110 million in the fourth quarter of 2021.
  • Reported net interest expense was $62 million in the fourth quarter of 2022, a 13% increase as compared to the fourth quarter of 2021.
  • The adjusted effective tax rate was negative 22.0% in the fourth quarter of 2022 as compared to 19.2% in the fourth quarter of 2021.
  • Adjusted EBITDA was $174 million in the fourth quarter of 2022, a decrease of 19% compared to the fourth quarter of 2021.

Elanco Adds Animal Health Veteran to Executive Committee

Retrieved on: 
Monday, February 20, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, ELAN, Marketing management, Boehringer Ingelheim, Marketing, NYSE, Western Sydney University, Acquisition, Reg Bettington, Livestock, University, Novartis, Commercial Operating System, Macquarie Graduate School of Management, Growth, Poultry, Management, Pig, Elanco, Zoetis, Cattle

Elanco Animal Health (NYSE: ELAN) announced today the appointment of Tim Bettington as the company’s executive vice president Corporate Strategy and Market Development.

Key Points: 
  • Elanco Animal Health (NYSE: ELAN) announced today the appointment of Tim Bettington as the company’s executive vice president Corporate Strategy and Market Development.
  • Tim has built some of the industry’s most successful portfolios and overseen some of the most significant commercial businesses in animal health.
  • Prior to Zoetis, he served as North American Region Head of Commercial Operations for Boehringer Ingelheim’s animal health business.
  • In roles at Zoetis, Boehringer Ingelheim and Novartis Animal Health, Bettington developed deep expertise in sales excellence, product launch, strategy and business integration.

Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2022 Financial Results Announcement

Retrieved on: 
Friday, February 3, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, ELAN, Elanco, NYSE, Pharmaceutical industry, Video game

Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.
  • Elanco will also conduct a conference call on that day with the investment community and media to further detail the company’s performance.
  • The conference call will begin at 8:00 a.m. eastern time.
  • Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco’s website at https://investor.elanco.com/events-and-presentations/default.aspx .

Animal wound care Market Size by Product (Surgical Staplers, Surgical Sutures, Automated Suturing Devices, Surgical Sealants and Adhesives), By Application (Retail, E-Commerce, Veterinary Hospital and Clinic), Global Trends and Forecast till 2029

Retrieved on: 
Thursday, February 2, 2023
Global Animal Partnership, Human, Diagnosis, Pain, Obesity, Clifton Springs Hospital & Clinic, Ageing, Elanco, Diabetes, USD, Growth, Infection, Pithing, Conditional sentence, Prevalence, COVID-19, Hygiene, Nursing, Animal

PUNE, India, Feb. 2, 2023 /PRNewswire/ --

Key Points: 
  • Animal wound care Market Overview:
    The global Animal wound care Market is currently valued at USD 1.85billion and is expected to reach USD 1.00 billion by the end of 2029, growing at a CAGR of 7.1% over the next decade.
  • The key growth drivers for this Animal wound care Market:
    The key growth drivers for the global animal wound care market are increasing awareness of veterinary services and products in urban households and growing adoption of alternative therapies among consumers.
  • Animal wound care Market Share Insights: North America (41%) accounts for the largest share of the global Animal wound care Market due to significant presence of key market players in the region.
  • The animal wound care market defines different types of Products:  Surgical Wound Care Products, Advanced Wound Care Products, Traditional Wound Care Products, and Therapy Devices
    There are 2 types of animals in the animal wound care market: Companion Animals, Livestock Animals
    In the animal wound care market end-use industry segment defines 2 types of end users: Hospitals & Clinics, Home Care Settings
    Animal wound care Market Report Scope:

Animal wound care Market Size by Product (Surgical Staplers, Surgical Sutures, Automated Suturing Devices, Surgical Sealants and Adhesives), By Application (Retail, E-Commerce, Veterinary Hospital and Clinic), Global Trends and Forecast till 2029

Retrieved on: 
Thursday, February 2, 2023
Global Animal Partnership, Human, Diagnosis, Pain, Obesity, Clifton Springs Hospital & Clinic, Ageing, Elanco, Diabetes, USD, Growth, Infection, Pithing, Conditional sentence, Prevalence, COVID-19, Hygiene, Nursing, Animal

PUNE, India, Feb. 2, 2023 /PRNewswire/ --

Key Points: 
  • Animal wound care Market Overview:
    The global Animal wound care Market is currently valued at USD 1.85billion and is expected to reach USD 1.00 billion by the end of 2029, growing at a CAGR of 7.1% over the next decade.
  • The key growth drivers for this Animal wound care Market:
    The key growth drivers for the global animal wound care market are increasing awareness of veterinary services and products in urban households and growing adoption of alternative therapies among consumers.
  • Animal wound care Market Share Insights: North America (41%) accounts for the largest share of the global Animal wound care Market due to significant presence of key market players in the region.
  • The animal wound care market defines different types of Products:  Surgical Wound Care Products, Advanced Wound Care Products, Traditional Wound Care Products, and Therapy Devices
    There are 2 types of animals in the animal wound care market: Companion Animals, Livestock Animals
    In the animal wound care market end-use industry segment defines 2 types of end users: Hospitals & Clinics, Home Care Settings
    Animal wound care Market Report Scope:

Veterinary Vaccine Market Size to Reach USD 13,681.4 Million in 2030| Emergen Research

Retrieved on: 
Wednesday, January 4, 2023
Human, Veterinary medicine, Mortality, USD, Vaccination, Sustainable Development Goals, Lethargy, DVM, RNA, Municipal government in Canada, Student, Dog, University, United Nations Sustainable Development Group, Eli Lilly and Company, Zoonosis, Government, Growth, National Center for Biotechnology Information, CDC, Livestock, Risk, Food security, Disease, National Center for Immunization and Respiratory Diseases, Lead, DNA, Prevalence, Anaphylaxis, Society for the Prevention of Cruelty to Animals, Infection, Centers for Disease Control and Prevention, Clinical and Vaccine Immunology, Fever, Cat, Allergy, Vaccine, Merck & Co., Pet, Society, PETS, Animal, Elanco

VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .
  • Increasing adoption of pets, rising prevalence of zoonotic diseases, and surging cases of COVID-19 are some key factors driving veterinary vaccine market revenue growth.
  • According to the report, it was stated that USD 59 million has been allocated to the provincial budget for 2022 to increase the Doctor of Veterinary Medicine (DVM) program.
  • The veterinary vaccine market is expected to register a CAGR of 6.2% over the forecast period and revenue is projected to increase from USD 7,975.3 Million in 2021 to USD 13,681.4 Million in 2030.

Veterinary Vaccine Market Size to Reach USD 13,681.4 Million in 2030| Emergen Research

Retrieved on: 
Wednesday, January 4, 2023
Human, Veterinary medicine, Mortality, USD, Vaccination, Sustainable Development Goals, Lethargy, DVM, RNA, Municipal government in Canada, Student, Dog, University, United Nations Sustainable Development Group, Eli Lilly and Company, Zoonosis, Government, Growth, National Center for Biotechnology Information, CDC, Livestock, Risk, Food security, Disease, National Center for Immunization and Respiratory Diseases, Lead, DNA, Prevalence, Anaphylaxis, Society for the Prevention of Cruelty to Animals, Infection, Centers for Disease Control and Prevention, Clinical and Vaccine Immunology, Fever, Cat, Allergy, Vaccine, Merck & Co., Pet, Society, PETS, Animal, Elanco

VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .

Key Points: 
  • VANCOUVER, B.C., Jan. 4, 2023 /PRNewswire/ -- The veterinary vaccine market size reached USD 7,975.3 Million in 2021 and is expected to register a CAGR of 6.2% during the forecast period, according to latest analysis by Emergen Research .
  • Increasing adoption of pets, rising prevalence of zoonotic diseases, and surging cases of COVID-19 are some key factors driving veterinary vaccine market revenue growth.
  • According to the report, it was stated that USD 59 million has been allocated to the provincial budget for 2022 to increase the Doctor of Veterinary Medicine (DVM) program.
  • The veterinary vaccine market is expected to register a CAGR of 6.2% over the forecast period and revenue is projected to increase from USD 7,975.3 Million in 2021 to USD 13,681.4 Million in 2030.

Elanco Announces FDA Approval of Bexacat™ (bexagliflozin tablets) – the First-of-its-Kind Oral Feline Diabetes Treatment Option

Retrieved on: 
Friday, December 9, 2022
Veterinary, FDA, Pets, Other Natural Resources, Health, Consumer, Pharmaceutical, Agriculture, Natural Resources, PETS, Elanco, Cat, Insulin, Veterinarian, Diabetes, ELAN, Coma, Weakness, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Needle, Research, Clinical Science (journal), Diarrhea, Prevalence, Animal, Purdue University, Dehydration, College, Death, NYSE, Family, Liver, Disease, FDA, Vomiting, Professor, Weight loss, Human, Type 1 diabetes, Ohio State University, Diabetic ketoacidosis, Purging disorder, SGLT2, Lethargy, Veterinary medicine, Health, Depression, Farmer, Risk, Pharmaceutical industry, Birth control, Food

Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA in any animal species.

Key Points: 
  • Bexacat is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA in any animal species.
  • Bexacat introduces a new mechanism of action for veterinarians and pet owners that offers a non-insulin, needle-free, once-daily oral medication specifically designed for cats with diabetes mellitus.
  • This first-in-class therapeutic is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin.
  • Bexacat integrates seamlessly into the busy lifestyle of pet owners and provides a needle-free approach to managing diabetes in cats.

Elanco to Participate in Evercore ISI 5th Annual HealthCONx Conference

Retrieved on: 
Wednesday, November 16, 2022
Veterinary, Agriculture, Natural Resources, Pets, Health, Consumer, Other Natural Resources, Other Health, PETS, Animal, Conference, NYSE, Veterinarian, ELAN, Elanco, Disease, Farmer, Evercore, Health, Food

Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022.
  • Jeff Simmons, president and CEO, will participate in a fireside chat at 8:50 a.m., Eastern time.
  • A live audio webcast will be available in the Events and Presentations section of Elancos investor website .
  • At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our approach to sustainability, Elanco Healthy Purpose all to advance the health of animals, people, planet, and our enterprise.